Lexapro (Escitalopram) in a 9-Year-Old with Autism and Intermittent Food Refusal
Lexapro is FDA-approved for generalized anxiety disorder in children 7 years and older, but is NOT approved for autism spectrum disorder, and the child's intermittent food refusal represents a critical contraindication that must be addressed before initiating this medication. 1
Critical Safety Concerns
Age and Indication Appropriateness
- Lexapro is FDA-approved starting at age 7 for GAD only 1
- The medication has no FDA approval for treating autism spectrum disorder at any age 1
- For depression, FDA approval begins at age 12, not 9 1
The Food Refusal Problem
This is the most concerning issue. SSRIs including escitalopram commonly cause:
- Appetite changes and weight loss as frequent adverse effects 2
- Nausea, diarrhea, and abdominal pain (>10% incidence) 3
- These side effects emerge within the first few weeks of treatment 2
In a child who already intermittently refuses to eat, adding a medication that frequently suppresses appetite and causes GI distress creates substantial risk for:
- Worsening nutritional status
- Dangerous weight loss
- Inability to distinguish medication side effects from underlying behavioral symptoms
- Treatment failure due to intolerable adverse effects
If Proceeding Despite Concerns (For Anxiety, Not Autism)
Starting Dose and Titration
Per FDA labeling for pediatric GAD (ages 7+) 1:
- Start: 10 mg once daily (morning or evening, with or without food)
- Titration interval: No less than 2 weeks between dose increases
- Maximum dose: 20 mg daily
This differs from the AACAP guideline recommendation for slow up-titration to avoid behavioral activation, which is more common in younger children 2. The 2-week minimum interval is already conservative but may need to be extended further in this high-risk patient.
Critical Pre-Treatment Requirements
Before prescribing 1:
- Screen for personal/family history of bipolar disorder, mania, or hypomania
- Document baseline weight, height, and eating patterns
- Establish clear target symptoms (anxiety-related, not autism core features)
Monitoring Protocol
Weeks 1-4 (Acute Phase):
- Weekly visits to monitor for:
- Suicidal ideation/behavior (boxed warning through age 24) 2, 1
- Behavioral activation/agitation (motor restlessness, insomnia, impulsiveness, aggression—more common in younger children) 2
- Weight and appetite changes (critical in this patient)
- GI symptoms (nausea, abdominal pain, diarrhea)
- Other common side effects: headache, insomnia, dizziness
Weeks 6-12:
- Visits every 2 weeks
- Clinical improvement typically seen by week 6, maximal by week 12 2
- Continue monitoring weight, eating patterns, and behavioral symptoms
Key Monitoring Points:
- The NNH for suicidal ideation is 143 vs. NNT of 3 for response 2
- Behavioral activation usually occurs early in treatment or with dose increases and improves quickly with dose reduction 2
- Serotonin syndrome risk if combined with other serotonergic agents 2
Evidence Specific to Autism
Research in ASD populations shows mixed and limited evidence for escitalopram:
- One pharmacogenetic study found CYP2C19 ultrarapid metabolizers showed reduced tolerance to fixed titration schedules 4
- Another study found genotype-dependent response variability, with some genotypes showing minimal benefit 5
- No robust evidence supports escitalopram for autism core features or irritability 6, 7
Alternative Considerations
For irritability/behavioral symptoms in autism, risperidone and aripiprazole have FDA approval and stronger evidence 8, 6, 7. For anxiety in ASD specifically, recent guidelines suggest buspirone or mirtazapine may be preferred over SSRIs 7.
Common Pitfalls to Avoid
- Do not use SSRIs to treat autism core features—they are ineffective for this purpose
- Do not ignore the eating problem—it will likely worsen on escitalopram
- Do not rush titration—younger children need slower increases to minimize behavioral activation
- Do not miss bipolar screening—antidepressants can precipitate mania
- Do not combine with other serotonergic agents without careful monitoring for serotonin syndrome
Bottom Line
Address the food refusal first through behavioral intervention and medical evaluation before considering any appetite-suppressing medication. If anxiety is the primary target and warrants pharmacotherapy, ensure the family understands this is off-label for autism, that eating problems may worsen, and that weekly monitoring is mandatory. Consider consulting a child psychiatrist with autism expertise before proceeding. 2, 1, 7